Actuate Therapeutics Inc (ACTU)

May 23, 2026

Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com India

May 23, 2026

May 23, 2026

Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart

May 23, 2026

May 22, 2026

Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor - TipRanks

May 22, 2026

May 22, 2026

Actuate Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com

May 22, 2026

May 22, 2026

Actuate Therapeutics, Inc.Common stock (NQ: ACTU - The Chronicle-Journal

May 22, 2026

May 22, 2026

Actuate Therapeutics (ACTU) Holds Near Support After Modest UptickCrowd Breakout Signals - Newser

May 22, 2026

May 19, 2026

ACTU Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus

May 19, 2026

May 18, 2026

Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co. - Moomoo

May 18, 2026

May 15, 2026

Actuate Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2026

May 14, 2026

Actuate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026

May 13, 2026

Actuate Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView

May 13, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 11, 2026

Actuate Wins FDA Clearance for Oral Elraglusib Trial - TipRanks

May 11, 2026

May 11, 2026

Actuate Therapeutics (NASDAQ: ACTU) gets FDA IND ok but flags cash risk - Stock Titan

May 11, 2026

May 11, 2026

Actuate Therapeutics Announces FDA Clearance of IND for - GlobeNewswire

May 11, 2026

May 11, 2026

Pancreatic cancer drug elraglusib moves to pill form after survival gains - Stock Titan

May 11, 2026

May 06, 2026

Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks

May 06, 2026

May 06, 2026

Actuate Therapeutics Adds Oncology Veteran Martin Huber to Board as Elraglusib Advances - citybiz

May 06, 2026

May 06, 2026

Actuate Therapeutics appoints Martin Huber to board - Investing.com

May 06, 2026

May 06, 2026

Actuate Therapeutics appoints Martin Huber to board By Investing.com - Investing.com Australia

May 06, 2026

May 06, 2026

Actuate Therapeutics Appoints Dr. Martin Huber as Independent Director to Strengthen Leadership Team - Quiver Quantitative

May 06, 2026

May 06, 2026

Cancer drug developer Actuate taps ex-Mersana CEO for board seat - Stock Titan

May 06, 2026

May 06, 2026

Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026 - marketscreener.com

May 06, 2026

Apr 29, 2026

Actuate Therapeutics (ACTU) price target decreased by 17.00% to 21.16 - MSN

Apr 29, 2026

Apr 28, 2026

Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1% - MarketBeat

Apr 28, 2026

Apr 27, 2026

Actuate Therapeutics announces public offering of common stock - MSN

Apr 27, 2026

Apr 22, 2026

Why did Actuate Therapeutics (ACTU) stock jump over 14% after hours? - MSN

Apr 22, 2026

Apr 22, 2026

Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - whbl.com

Apr 22, 2026

Apr 22, 2026

H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Apr 22, 2026

Apr 22, 2026

HC Wainwright Reiterates "Buy" Rating for Actuate Therapeutics (NASDAQ:ACTU) - MarketBeat

Apr 22, 2026

Apr 22, 2026

H.C. Wainwright reiterates Buy on Actuate Therapeutics stock By Investing.com - Investing.com Canada

Apr 22, 2026

Apr 22, 2026

Actuate Therapeutics Inc - Reuters

Apr 22, 2026

Apr 21, 2026

12 Health Care Stocks Moving In Tuesday's After-Market SessionActuate Therapeutics (NASDAQ:ACTU), Celu - Benzinga

Apr 21, 2026

Apr 21, 2026

Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - TradingView

Apr 21, 2026

Apr 17, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 17, 2026

Apr 17, 2026

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? - Sahm

Apr 17, 2026

Apr 15, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Apr 15, 2026

Apr 15, 2026

HC Wainwright Issues Optimistic Estimate for ACTU Earnings - National Today

Apr 15, 2026

Apr 15, 2026

B.Riley cuts Actuate Therapeutics stock price target on revenue timing - Investing.com

Apr 15, 2026

Apr 14, 2026

Actuate Therapeutics Reports Significant Survival Improvement in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Quiver Quantitative

Apr 14, 2026

Apr 14, 2026

Pancreatic cancer trial doubled one-year survival in study - Stock Titan

Apr 14, 2026

Apr 14, 2026

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire

Apr 14, 2026

Apr 14, 2026

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - Nature

Apr 14, 2026

Apr 13, 2026

ACTU Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Apr 13, 2026

Apr 13, 2026

H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $15 - Moomoo

Apr 13, 2026